Informatics Publishing Limited

S. Thillaivanan ¹, S. Susikannamma ², P. Parthiban ³, V. Ganesh ³, A. Shanmugasundaram ⁴

Affiliations
1 Government Hospital, Pernambut, Vellore – 635810, Tamil Nadu, IN
2 District Siddha Medical Hospital, Vellore, Tamil Nadu, IN
3 Indian Medicine and Homeopathy Department, Chennai – 600106, Tamil Nadu, IN
4 District Collector’s Office, Vellore – 632009, Tamil Nadu, IN

Abstract

Siddha's system of medicine is the effective one to reduce the symptoms of many viral illnesses. Siddha's system of medicine in asymptomatic, mild to moderate Covid-19 Positive patients, will make them recognize its effectiveness, reduce the symptoms, and move into the traditional approach towards the deadliest pandemic disease Covid-19. The objective of this study is to evaluate the acceptance and benefit of integrative Siddha management among the mild, moderate and asymptomatic COVID patients through a feedback questionnaire in TPEC COVID Care Center, Vellore, Tamil Nadu (TPECThanthai Periyar Engineering College). 74 asymptomatic, mild to moderate Covid-19 Positive patients were observed 7 days from 14.07.2020 to 30.07.2020 in TPEC COVID Care Center, Vellore, Tamil Nadu. During this period, Siddha medicines were administrated along with Western medicine. At the end of the period, validated feedback questionnaires were used to collect information from 74 participants for evaluating the acceptance and benefit of integrative Siddha management.In the 74 patients of TPEC COVID Care Center, Vellore, 100% were taken the given Siddha drug properly. 82.4% had the most common symptoms and 52.7% had less common symptoms. 16.2% of cases developed gastric acidity and 1.3% developed mild dyspnea as an ADR. 91.8% were recommended the Siddha system to others. 93.2% reported excellent disease progress. 90.7% of Siddha doctors quoted for 'Excellent' service on covid patients. This feedback report explores the three important significance. (a) Siddha medicine having significant effectiveness (b) Siddha medicines have safety in covid-19 patients (c) overall services of Siddha doctors are appreciatable by the patients and Siddha system is recommended to others. This analysis report helps to provide the possibility of the Siddha system for further or future clinical trials.

Keywords

COVID Care Center, Integrative Medicine, SARS CoV-2, Novel Corona Virus, Siddha System of Medicine.

Full Text

   

S. Karthik Nagarajan ¹, M. Bakkiya Devi ², S. Thillaivanan ³, K. S. Maanickha Chelvi ¹, A. Kanagarajan ¹

Affiliations
1 Siddha Regional Research Institute, Under CCRS, Ministry of Ayush, Government of India, Thiruvananthapuram - 695012, Kerala, IN
2 National Institute of Siddha, Ministry of Ayush, Government of India, Chennai - 600047, Tamil Nadu, IN
3 Department of Indian Medicine and Homeopathy, Government of Tamil Nadu, IN

Abstract

Background: Covid-19 disease is a Wuhan, China originated acute viral respiratory illness. Even though the development of numerous vaccines, the threat of the Covid-19 virus endures nearly two years after the outbreak. The new mutant strain omicron has now spread to several countries. As a result, newer antiviral therapy is required to overcome this scenario. Objective: This study is aimed at phytocomponents in the Siddha formulation, Vishasura Kudineer (VSK), it is widely used to manage fever and respiratory ailments and may be effective in combating the ongoing pandemic of novel coronavirus disease. Methodology: The principal protease 3CLpro of this new Coronavirus (SARS-CoV-2) is a possible focus for therapeutic development since it plays a major part in disease transmission. Molecular docking investigation for all active Phytocomponents found in the Siddha formulation Vishasura Kudineer with possible targets was carried in the major Protease of SARS-CoV-2 (PDB ID:6LU7). AutoDockTools was used to design and optimize the ligand structures. Results: Molecular docking of the 9 bioactive phytocomponents as Santalic acids (-6.39), Nimbolide (-6.38), Rutin, Aristolochic acid (-6.95), Glabridin (-7.53), Indirubin (-7.23), Sabinene (-5.36), β-vetivenene (-6.79), and Zingiberene (-6.47) from in the Siddha sastric formulation, Vishasura Kudineer performed on the SARS-CoV-2 Main Protease protein’s active site (PDB ID: 6LU7). These phytochemicals had significant molecular interaction with the active residues, indicating their distinct inhibitory potencies. Conclusion: Whether this Siddha formulation could be used to effectively treat and manage COVID-19 and its variants, further research and clinical studies need to be done.

Keywords

Ayush, COVID-19, Molecular Docking, Network Pharmacology, Siddha Medicine

Full Text